Novo Nordisk A/S $NVO Shares Sold by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 20.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 42,000 shares of the company’s stock after selling 10,500 shares during the quarter. Hussman Strategic Advisors Inc.’s holdings in Novo Nordisk A/S were worth $2,331,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. True Wealth Design LLC increased its stake in shares of Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after acquiring an additional 300 shares during the last quarter. NewSquare Capital LLC increased its position in Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after purchasing an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. purchased a new position in Novo Nordisk A/S during the second quarter worth about $37,000. Steigerwald Gordon & Koch Inc. acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at about $39,000. Finally, Copeland Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 47.3% in the 2nd quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock valued at $40,000 after buying an additional 186 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $62.90 on Wednesday. The company has a market cap of $280.86 billion, a P/E ratio of 18.29 and a beta of 0.66. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a fifty-two week low of $43.08 and a fifty-two week high of $93.80. The firm’s 50 day moving average price is $52.75 and its 200 day moving average price is $54.50.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.25. The firm had revenue of $11.79 billion for the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. On average, research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on NVO shares. CICC Research initiated coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 price target on the stock. Morgan Stanley reaffirmed an “underweight” rating and issued a $42.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, December 3rd. Hsbc Global Res cut Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, December 29th. Finally, Jefferies Financial Group started coverage on shares of Novo Nordisk A/S in a research report on Monday, October 27th. They issued an “underperform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $57.79.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.